Announcements
- RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
- RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
- RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
- RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
- RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
- RAPT Therapeutics Reports Third Quarter 2023 Financial Results
- RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
More ▼
Key statistics
On Friday, RAPT Therapeutics Inc (0RA:FRA) closed at 7.30, 14.06% above the 52 week low of 6.40 set on Feb 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.35 |
---|---|
High | 7.35 |
Low | 7.30 |
Bid | -- |
Offer | -- |
Previous close | 7.45 |
Average volume | 89.00 |
---|---|
Shares outstanding | 34.80m |
Free float | 32.02m |
P/E (TTM) | -- |
Market cap | 275.96m USD |
EPS (TTM) | -3.05 USD |
Data delayed at least 15 minutes, as of Apr 19 2024 14:29 BST.
More ▼